Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q4 FY2024 Earnings Presentation
31 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, May 15, 2024
Slide 1: Cover letter to stock exchanges
15th May 2024 IOLCP/CGC/2024 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Dalal Street, Mumbai- 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Investor Presentatio
Slide 2: Q4 & FY24 Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Q4 & FY24 Investor Presentation May 2024
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the “Companies”, IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on i
Slide 4: Table of Contents
Table of Contents 01 IOLCP at a glance 02 Financial Highlights 03 Company Overview Standalone Quarterly Income Statement The Journey About IOL Chemicals and Pharmaceuticals Ltd. Standalone Income - Sustained revenue Core management team Q4 FY24 & FY24 Performance Standalone Balance Sheet - Building
Slide 5: IOL Chemicals & Pharma - Overview
IOL Chemicals & Pharma - Overview Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2750+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited) Debt free
Slide 6: Q4 & FY24 Performance
Q4 & FY24 Performance Key Updates Q4FY24 Financial Performance • Received approval from Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA), China to export Metformin Hydrochloride” in China Market 511.4 57.6 11.3% Total Income (₹ cr) EBITDA (₹ cr) EBITDA Margin • Suc
Slide 7: Geographical and Segmental highlights
Geographical and Segmental highlights Chemical Segment (₹ crore) Pharma Segment (₹ crore) 219 11 233 12 400 368 100 214 211 349 207 332 200 295 287 80 300 80 8 150 10 60 200 100 50 40 4 50 100 35 39 50 1 1 20 3 0 0 0 0 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Revenue (ne
Slide 8: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 9: Standalone Quarterly Income Statement
Standalone Quarterly Income Statement Particulars (₹ Cr) Q4 FY24 Q4 FY23 YoY Q3 FY24 QoQ Revenues 503.9 587.2 -14.2% 520.4 Other Income 7.5 8.7 8.4 Total Income 511.4 595.9 -14.2% 528.8 -3.3% Total Expenses 453.8 491.4 475.9 EBITDA 57.6 104.5 -44.9% 52.90 8.9% EBITDA Margin (%) 11.3% 17.5% -620bps 1
Slide 10: Standalone Income - Sustained revenue
Standalone Income - Sustained revenue Particulars (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 Revenues 1,685.3 1,894.5 1,967.0 2,184.0 2,217.1 2,132.8 Other Income 10.4 16.0 24.3 32.0 25.6 30.1 Total Income 1,695.7 1,910.5 1,991.3 2,216.0 2,242.7 2,162.9 Total Expenses 1,275.7 1,320.6 1,375.2 1,927.6 1,990
Slide 11: Standalone Balance Sheet - Building assets
Standalone Balance Sheet - Building assets Balance Sheet (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 Shareholders' Funds 474.3 813.5 1260.4 1390.3 1506.6 1611.3 Long-term Debt 284.0 56.0 0.0 0.0 0.0 0.0 Total Non-current Liabilities 20.8 79.7 59.1 56.6 58.1 72.9 Total Current Liabilities 162.8 220.6 290.6
Slide 12: Standalone Cash Flow Statement
Standalone Cash Flow Statement Particulars (₹ Cr) FY19 FY20 FY21 FY22 FY23 FY24 Profit before tax 336.2 533.2 571.4 222.8 189.5 182.6 Adjustments for: Non Cash Items / Other 82.4 51.9 27.2 33.1 44.4 60.1 Investment or Financial Items Operating profit before working capital changes 418.5 585.2 598.5
Slide 13: 5-years Performance
5-years Performance Operational Revenue (₹ Cr) EBITDA (₹ Cr) and EBITDA Margin (%) PAT (₹ Cr) and PAT Margin (%) 2,216 2,243 2,163 30.9% 30.9% 22.3% 1,911 1,991 1,696 24.8% 18.9% 11.2% 14.0% 13.0% 12.1% 7.5% 6.3% 6.2% 420 590 616 288 252 262 237 361 445 166 140 135 FY19 FY20 FY21 FY22 FY23 FY24 FY19
Slide 14: Diversified revenue base
Diversified revenue base FY19 FY23 FY24 568, 34% 955, 43% 865, 41% 476, 22% 431, 20% 128, 7% 989, 59% 786, 35% 837, 39% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's 13 * Amt in ₹ crore
Slide 15: Company Overview
COMPANY OVERVIEW
Slide 16: The Journey
The Journey ▪ 2009 - Commencement of ▪ 1996 - Commencement of ▪ 2015 - USFDA, EIR for ▪ Paracetamol capacity IBB, MCA and Acetyl Ethyl Acetate Plant Ibuprofen ▪ 2019 - Unit-06 for has been increased to Chloride Plants ▪ 1999 - Commencement of ▪ 2016 - Unit-03 for new Pantoprazole (Dedicated) 3,600 T
Slide 17: Core management team
Core management team Varinder Gupta (Managing Director) ▪ Wide and rich experience of more than 35 years in the chemical & fertilizer industry and along Vikas Gupta with a comprehensive approach and strong (Joint Managing Director) Pharma API industry oversight has paved a way ▪ Academically equippe
Slide 18: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) ▪ With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh ▪ In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 19: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility EUGMP Certification in 2013, Certified Halal in accordance Certificate of DMF ISO 9001:2015, since 2015, recertified in Certificate of Suitability 2017 & Recertification in with Shariah Board Registration From MFDS 14001:2015 & 2019 from EDQM
Slide 20: Business Overview
BUSINESS OVERVIEW
Slide 21: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT Product application across various therapeut
Slide 22: Specialty chemicals – capitalizing on global demand
Specialty chemicals – capitalizing on global demand IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA • Commenced
Slide 23: Manufacturing facilities
Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 3 5 intermediates & Specialty chemicals in Dedicated and multiproduct blocks system, PSA Nitrogen & Purified water continuous product delivery manner involved in manufacturing of APIs along with
Slide 24: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Environment • Committed to ensure that our operations have minimal • Our continuous efforts have resulted in a 3.91% impact on the environment reduction in Scope-01 greenhouse gas (GHG) • Constantly monitoring environmental footprints and imple
Slide 25: Industry Overview
INDUSTRY OVERVIEW
Slide 26: Pharmaceuticals – Emerging strongly out of pandemic
Pharmaceuticals – Emerging strongly out of pandemic Indian API Market World Pharmaceutical Industry • The Indian API market is expected to grow at a CAGR of 13.7% over the four years • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. $1.6 8-10% $2.4 Trilli
Slide 27: Specialty Chemicals – an era of sustained robust growth
Specialty Chemicals – an era of sustained robust growth Short-term growth to remain subdued… • Demand headwinds from export markets, China’s rising supplies and inventory destocking have impacted margins & profitability of Indian players • Expectations of sluggish global growth, oversupplied industr
Slide 28: Way Forward
WAY FORWARD
Slide 29: Charting a path to success
Charting a path to success Four pronged strategy for growth Focus on Capacity Improved Expanding Regulated expansion in asset Non-Ibuprofen Pharma & utilization Markets Business Chemicals During the last six years, During the last six years Increased contribution Added more than 10 the Company’s tur
Slide 30: Expanding the non-Ibuprofen business
Expanding the non-Ibuprofen business (Analgesic and Antipyretic drugs) Multi Product facility focused on Paracetamol, with an Regulatory Filings: CEP installed capacity of approved; US DMF filed 3,600 MT/Annum, with a backward integration process (Antiplatelet drug, used in cardiovascular (Anticonsu
Slide 31: Thank You
Thank You Company : Investor Relations Advisors : IOL Chemicals and Adfactorspr Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, Darshan Mankad CFO darshan.mankad@adfactorspr.com pardeepkhanna@iolcp.com Hanishi Shah hanishi.shah@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q4 FY2024 Earnings Presentation on 6ix